CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0703 (clinicaltrials.gov NCT No: Not Registered)
Title:Randomized study of ibrutinib versus ibrutinib plus rituximab (i versus iR) in patients with relapsed chronic lymphocytic leukemia (CLL)
Principal Investigator:Jan A. Burger
Treatment Agent:Ibrutinib; Rituximab
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the combination of
ibrutinib and rituximab can help to control CLL better than ibrutinib alone.
The safety of these treatments will be also studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Ibrutinib
Rituximab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Pharmacyclics, Inc
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jan A. Burger
Dept:Leukemia
For Clinical Trial Enrollment:713-563-1487
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults